Aradigm Presents Data Demonstrating Significant Antibacterial Concentrations and Effects in Non-Cystic Fibrosis Bronchiectasis Patients Following Administration of its Once-Daily Inhaled Liposomal Ciprofloxacin.Aradigm is presenting results from its Phase 2a clinical trial in non-cystic fibrosis bronchiectasis bronchiectasis Abnormal expansion of bronchi in the lungs. It usually results when preexisting lung disease causes bronchial inflammation and obstruction. Bronchial wall fibres degenerate, and bronchi become dilated or paralyzed, preventing removal of secretions, which patients at the 2009 European Respiratory Society (ERS ERS, n.pr See extended rotated side-bent. ) Annual Congress. Additionally, Aradigm is presenting summary data on the pharmacokinetics of its once-daily inhaled liposomal ciprofloxacin ciprofloxacin /cip·ro·flox·a·cin/ (sip?ro-flok´sah-sin) a synthetic antibacterial effective against many gram-positive and gram-negative bacteria; used as the hydrochloride salt. cip·ro·flox·a·cin n. formulation (CFI CFI abbr. cost, freight, and insurance ) in CF patients and healthy volunteers. HAYWARD, Calif. -- Aradigm Corporation (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : ARDM) ("Aradigm") today announced it is presenting data from its Phase 1 and Phase 2a studies at the ERS Annual Congress in Vienna, Austria, September 12-16, 2009. The first presentation describes the significant antibacterial activity of CFI in the sputum sputum /spu·tum/ (spu´tum) [L.] expectoration; matter ejected from the trachea, bronchi, and lungs through the mouth. sputum cruen´tum bloody sputum. of non-cystic fibrosis bronchiectasis patients suffering from respiratory infections with Pseudomonas Aeruginosa Pseudomonas aeruginosa A normal soil inhabitant and human saprophyte that may contaminate various solutions in a hospital, causing opportunistic infection in weakened Pts Clinical Infective endocarditis in IVDAs, RTIs, UTIs, bacteremia, meningitis, 'malignant' . The second presentation describes the significant antibacterial activity of CFI in the sputum of cystic fibrosis cystic fibrosis (sĭs`tĭk fībrō`sĭs), inherited disorder of the exocrine glands (see gland), affecting children and young people; median survival is 25 years in females and 30 years in males. patients (CF) and elaborates on the pharmacokinetic parameters observed in the CF patients that were similar to those in healthy volunteers. Additionally, high concentrations of ciprofloxacin were measured in the sputum of CF patients. The overall results demonstrated pharmacokinetics of inhaled liposomal ciprofloxacin with a long systemic elimination half life (tu) of ~10.5 hours, supporting once-daily dosing and allowing for less frequent administration than current inhaled antibiotic regimens. This treatment resulted in high concentrations of ciprofloxacin in the sputum leading to a significant reduction in the number of colony forming units (CFU CFU see colony-forming units. ) of Pseudomonas Aeruginosa in the sputum, an objective measure of the reduction in pulmonary bacterial load in the CF and non-CF bronchiectasis patients. Ciprofloxacin is a widely prescribed antibiotic to treat infections of the lung frequently experienced by CF and non-CF bronchiectasis patients. It is often preferred because of its broad-spectrum antibacterial action. The available oral and intravenous formulations of the drug are used to treat episodes of acute exacerbations of lung infections. Aradigm's once-a-day inhaled formulation of ciprofloxacin delivered in liposomes Liposomes Aqueous compartments enclosed by lipid bilayer membranes; liposomes are also known as lipid vesicles. Phospholipid molecules consist of an elongated nonpolar (hydrophobic) structure with a polar (hydrophilic) structure at one end. (ARD Ard (ärd), in the Bible. 1 Son of Benjamin. 2 Benjamite, perhaps the same as (1.) An alternate form is Addar. 3100) is to be used for chronic maintenance therapy as it is expected to achieve higher antibiotic concentration at the site of infection and relatively low systemic antibiotic concentrations to minimize side-effects. About the 2009 ERS Annual Congress The 2009 ERS Annual Congress, a leading scientific meeting organized by the European Respiratory Society provides a unique forum where scientists and medical professionals from around the world have the opportunity to meet and exchange ideas and information in the field of respiratory medicine. More information about the 2009 ERS Annual Congress can be found at http://dev.ersnet.org/725-welcome-address.htm. About Aradigm Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, inhalation anthrax infections and smoking cessation. More information about Aradigm can be found at www.aradigm.com. Forward-Looking Statements Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including dosing regimens and the timing and results of clinical trials, as well as the other risks detailed in Aradigm Corporation's Securities and Exchange Commission (SEC) Filings, including Aradigm's Annual Report on Form 10-K, and quarterly reports on Form 10-Q. Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion